These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37029845)

  • 1. Risk prediction of esophageal squamous cell carcinoma recurrence in patients who underwent esophagectomy after receiving neoadjuvant treatment: a nationwide retrospective study in Japan.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Esophagus; 2023 Jul; 20(3):465-473. PubMed ID: 37029845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
    Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
    Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy.
    Hirohata R; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Jul; 48(7):1700-1709. PubMed ID: 38757868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy.
    Yu S; Zhang W; Ni W; Xiao Z; Wang X; Zhou Z; Feng Q; Chen D; Liang J; Fang D; Mao Y; Gao S; Li Y; He J
    Oncotarget; 2016 Aug; 7(34):55211-55221. PubMed ID: 27487146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic venous invasion is a predictor of prognosis in patients with esophageal squamous cell carcinoma undergoing ineffective neoadjuvant chemotherapy and surgery.
    Tanishima Y; Takahashi K; Nishikawa K; Ishikawa Y; Yuda M; Tanaka Y; Matsumoto A; Yano F; Eto K
    Esophagus; 2023 Oct; 20(4):651-659. PubMed ID: 37081314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Kakeji Y; Kono K; Kitagawa Y; Takeuchi H
    Esophagus; 2024 Jan; 21(1):2-10. PubMed ID: 37999900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Apr; 30(4):2176-2185. PubMed ID: 36528742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
    Sugase T; Kanemura T; Takeoka T; Matsuura N; Masuike Y; Shinno N; Hara H; Kitakaze M; Kubo M; Mukai Y; Sueda T; Hasegawa S; Akita H; Nishimura J; Wada H; Yasui M; Omori T; Miyata H
    Anticancer Res; 2024 Jan; 44(1):185-193. PubMed ID: 38159967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
    Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
    Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Preoperative Platelet to Lymphocyte Ratio Is Associated with a Greater Risk of Postoperative Complications and Hematogenous Recurrences in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Treatment.
    Sasahara M; Kanda M; Shimizu D; Takami H; Inokawa Y; Hattori N; Hayashi M; Tanaka C; Fujiwara M; Nakayama G; Kodera Y
    Dig Surg; 2023; 40(1-2):48-57. PubMed ID: 36893749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
    Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy for pT1a-m3/pT1b esophageal squamous cell carcinoma after endoscopic resection: Esophagectomy or chemoradiotherapy? A critical review.
    Tsou YK; Lee CH; Le PH; Chen BH
    Crit Rev Oncol Hematol; 2020 Mar; 147():102883. PubMed ID: 32014674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study.
    Kudou K; Saeki H; Nakashima Y; Kimura Y; Oki E; Mori M; Shimokawa M; Kakeji Y; Toh Y; Doki Y; Matsubara H
    Esophagus; 2022 Jan; 19(1):57-68. PubMed ID: 34510325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide Validation Study of the Prognostic Significance of Stratification Using Pathological Stage and Response to Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Ann Surg; 2023 Aug; 278(2):e234-e239. PubMed ID: 36538635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer.
    Kurogochi T; Honda M; Takahashi K; Okamura A; Imamura Y; Yamashita K; Kamiya S; Hayami M; Mine S; Watanabe M
    Surg Today; 2022 Apr; 52(4):660-667. PubMed ID: 34708307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.